recent recommendation' that all births from 24 weeks onwards should be registered were implemented this anomaly would largely disappear.
We are trying to establish the number of intrauterine deaths from Rh(D) haemolytic disease occurring before the 28th week of pregnancy and thus arrive at a valid estimate of the present overall mortality. Meanwhile we must hope that our mortality figures for England and Wales do not underestimate true mortality to the extent implied by the Oxford figures.
At some centres enormous progress has been made in preventing fetal losses in the second trimester-for example, at one the survival rate for hydropic and non-hydropic fetuses treated at or before the 25th week of gestation was higher than 80%.2 CYRIL A CLARKE P L MOLLISON A G W WHITFIELD Arbaprostil in bleeding peptic ulcer SIR,-Dr K Lauritsen and others (19 October, p 1093) claim to provide a challenge to the concept of "direct cytoprotection" in acute upper gastrointestinal tract bleeding. They base this on a study in which four doses of arbaprostil were given orally to patients suffering an acute bleed and undergoing concurrent nasogastric aspiration. It is doubtful whether under those conditions the drug would be in good contact with the bleeding area for a significant time, or be significantly absorbed. They do not mention whether nasogastric aspiration was continuous or intermittent, and what its temporal relation was to drug administration, nor do they say whether they tested their aspirate to see how much of the arbaprostil had been inadvertently removed.
The intragastric milieu at the time of an acute bleed is an unreliable and uncertain state. The study can certainly be said to have shown that giving arbaprostil orally did not achieve the desired effect, but this does not necessarily negate the concept.
SISTER JOSEPH St Bartholomew's Hospital, London EC IA 5BE ***The authors reply below.-ED, BM7.
SIR,-Sister Joseph is concerned about the ability of orally administered prostaglandins to reach the bleeding area. This problem should not be neglected, but, firstly, the dose used (50 tg every six hours) is well above the dose considered to be "cytoprotective" and, secondly, if synthetic prostaglandins are to be used in bleeding from peptic ulcer the only practical way ofadministering these agents is topical application. Intravenous administration yields unwanted systemic effects, including hypotension, which might be disastrous in these patients. The drug under investigation was dispensed as a 1 ml solution contained in a 30 ml glass bottle. Just before its administration the bottle was filled with distilled water and shaken vigorously for 60 seconds. Immediately after administration, which was via a nasogastric tube or by swallowing this 30 ml volume, the bottle was rinsed with an additional 30 ml of water and this volume was dispensed in the same manner. If nasogastric suction was conducted it was low pressure and intermittent for blood determination only, and all suction was stopped 30 minutes before and after administration of the drug.
We disagree with Professor M J S Langman and Dr K W Somerville (9 November, p 1351), who claim that the confidence limits round the major results of our study may include "marked benefit" of arbaprostil. We are well aware-as stated-that the sample was too small to exclude a marginal beneficial effect on mortality, but the 95% confidence intervals for the observed differences between arbaprostil and placebo in halting bleeding and preventing rebleeding do not include a marked benefit and disappointingly make a major advantage of arbaprostil unlikely. Our Altitude sickness SIR,-My wife and I have recently returned from a holiday in Peru, where we were members of a group of 24 people staying at one stage at 12 000 ft (Lake Titicaca) and going up by train at one stage to 14 000 ft. When we met our group at London Airport I was surprised at the number of elderly folk-one at least was 80 and there were several in their 70s, and during the holiday it transpired that several were receiving treatment for mild hypertension. One man in his mid-60s developed severe symptoms of altitude sickness and told me that he was taking antihypertensive drugs, including , blockers. He was very ill but recovered with the use ofoxygen. I summoned a Peruvian doctor, who gave me some advice, and 24 hours later we went down to a lower level and he seemed much better. Sadly, however, he died in the night; whether this was due to altitude sickness or some other problem I cannot say. The tour company's brochure (and indeed other brochures dealing with similar tours from other organisers) says nothing about the hazards of altitude sickness; indeed, it is only when you have paid your deposit that it is mentioned. I have written to suggest that this is too late, that something should be said in the brochure, and that potential travellers should be given an opportunity to write in for an advice sheet written by an expert for them to take to their own doctors for further consideration; I hope they will adopt this.
Meanwhile, because we in Britain do not see altitude sickness and have little experience of it, I am sure that the hazards of even moderate altitude should be drawn to the attention of doctors. Twelve thousand feet may not seem particularly high for the average healthy person, but for somebody who is already having problems on level ground it can lead to destabilisation and indeed death. I would like to draw the attention of the profession to this particular hazard, which, with increasing travel to such areas as the Andes and Himalayas, is going to be relevant to our advice to patients in the future. Secondly, if a suitable darkened room is available it can be used for both the normal diabetic clinic consultation and the taking of retinal photographs. We find it is often more convenient to photograph the left and right eyes on consecutive clinic visits, rather than to wait the 5-10 minutes necessary to allow the contralateral pupil to dilate. Performed in this way, photography of the fundus takes little more time than measurement of blood pressure.
Used in this way, no additional staff are required and after the initial capital outlay (of about £12000) the only running cost is the price of Polaroid film (about £1/patient), which compares favourably with the price of other investigations such as glycosylated haemoglobin.
Finally, the Polaroid photographs may be shown to both patients and medical staff and therefore have considerable educative potential. The immediacy of the technique is greatly appreciated by the patient, particularly if there are any retinal abnormalities, the nature of which can be shown and explained to the patient.
For these reasons we believe that the nonmydriatic camera is a major advance in screening for diabetic retinopathy.
R [umol/l (15 8 mg/100 ml), and known not to be on digoxin therapy, were analysed. All digoxin results were below the method detection limit of 0-26 nmol/l (0 2 ng/ml). It is reassuring that these findings have been confirmed and that the other methods tested also showed no cross reactivity.
In the latest report from a widely subscribed external quality control scheme (Wellcome Immunoassay, 1 April-2 September 1985) there were 549 laboratories measuring digoxin by 41 different assays, the five methods investigated by Drs McElnay and Hooyman accounting for about 200 of these laboratories. However, many other assays have not yet been validated in renal impairment and some centres are using assays which have been shown to involve appreciable interference.3
Unfortunately, at least one digoxin method shown to be unaffected by the presence of renal impairment shows cross reactivity when used with neonatal samples,4 and significant immunoreactivity in liver disease has just been reported in two further radioimmunoassays.5 Scientists and clinicians must investigate the conditions in
